Impact of fibrinogen-to-albumin ratio on the long-term prognosis of patients with advanced HER2-negative gastric cancer receiving immunochemotherapy

Table 4 Univariate and multivariate analyses of prognostic factors for overall survival

Factors	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Age (< 60 vs ≥ 60), years	1.12 (0.77-1.62)	0.563
Sex (male vs female)	0.97 (0.67-1.40)	0.856
Site (stomach vs gastric and esophageal binding)	1.11 (0.76-1.61)	0.595
ECOG (0 vs 1)	1.81 (1.23-2.65)	0.002	1.78 (1.21-2.61)	0.003
Histological (others vs adenocarcinoma)	0.77 (0.50-1.18)	0.234
FAR (low vs high)	2.56 (1.75-3.76)	< 0.001	2.33 (1.59-3.43)	< 0.001
Staging (3 vs 4)	1.95 (1.25-3.05)	0.004	1.93 (1.23-3.03)	0.005
CEA (< 3 vs ≥ 3), ng/mL	1.08 (0.74-1.57)	0.705
Liver metastasis (no vs yes)	1.20 (0.82- 1.75)	0.354
Peritoneal metastasis (no vs yes)	1.21 (0.73-1.98)	0.459
EBV status (infect vs no-infect)	0.71 (0.42- 1.20)	0.200
PD-L1 expression (CPS < 5 vs CPS ≥ 5)	0.49 (0.31-0.77)	0.002	0.45 (0.29-0.71)	< 0.001
MMR status (dMMR vs pMMR)	1.38 (0.61-3.16)	0.441
BMI (< 25 vs ≥ 25), kg/ m2	0.59 (0.36-0.89)	0.013	0.61 (0.39-0.96)	0.033

HR: Hazard ratio; FAR: Fibrinogen-to-albumin ratio; ECOG: Eastern Cooperative Oncology Group; CEA: Carcinoembryonic-antigen; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair.